Unified Patent Court (UPC) analytics are now available. Check here

EP2896397

MITSUBISHI TANABE PHARMA
Application Number
EP14194507A
Filing Date
Jul 30, 2004
Status
Patent Maintained As Amended
Sep 4, 2020
Grant Date
Oct 7, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP2896397B2 was granted on Oct 7, 2020 by Mitsubishi Tanabe Pharma The patent is currently Patent Maintained As Amended.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLJun 6, 2018ADMISSIBLE
GENERICS UKJun 5, 2018ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionGB2359554
N/A
OppositionUS2003114390
N/A
OppositionEP1609785
N/A
OppositionWO0127128
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.